You are here: Industry Insights > SOC

News List

Pegcetacoplan safe and effective in paroxysmal nocturnal haemoglobinuria trial europeanpharmaceuticalreview
May 27, 2021
In a Phase III study pegcetacoplan resulted in 86 percent of treatment-naïve paroxysmal nocturnal haemoglobinuria (PNH) patients achieving haemoglobin stabilisation.
Ampio’s inhaled drug lowers mortality in Covid-19 trial pharmaceutical-technology
April 28, 2021
Ampio Pharmaceuticals has reported that its AP-014 Phase I clinical trial of inhaled drug Ampion showed a 78% improvement in all-cause mortality in Covid-19 patients with respiratory distress.
Leukine® significantly improves lung function in hospitalised COVID-19 patients europeanpharmaceuticalreview
March 01, 2021
In the trial Leukine® (sargramostim, rhuGM-CSF) improved oxygenation in COVID-19 patients with acute respiratory failure by at least a third in over half of those treated.
First hospitalised COVID-19 patient dosed in FSD201 treatment trial europeanpharmaceuticalreview
December 18, 2020
The study will evaluate whether FSD201 is safe and of benefit to hospitalised patients with COVID-19, in combination with standard of care.
Ruxolitinib (Jakafi) does not prevent complications due to COVID-19 associated cytokine storm: Study expresspharma
December 15, 2020
Incyte announced that the Phase 3 RUXCOVID study evaluating the safety and efficacy of ruxolitinib (Jakafi), a JAK1/JAK2 inhibitor, plus standard-of-care (SoC) as a treatment for patients 12 years and older with COVID-19 associated cytokine storm did ...
Canakinumab Study Fails to Meet Primary Endpoint americanpharmaceuticalreview
November 17, 2020
Novartis announced new data from an interim analysis for the randomized, double-blind, placebo-controlled CAN-COVID trial evaluating the efficacy and safety of canakinumab in hospitalized patients with COVID-19 pneumonia and cytokine release syndrome.
Ampio Begins Phase Trial of Inhaled Ampion for COVID-19 Patients with Respiratory Distress americanpharmaceuticalreview
November 02, 2020
Ampio Pharmaceuticals has begun recruiting and enrolling patients in a Phase I multi-center, randomized, controlled trial for a total of 40 patients that will assess the safety and efficacy of inhaled Ampion added to the standard of care (SOC) for ...
Octapharma USA extends funding for Covid-19 study following positive preliminary research data pharmaceutical-business-review
June 08, 2020
Following positive preliminary data, Octapharma USA is extending funding for an investigator-initiated study (IIS) focused on treating the most critical patients at the heart of the coronavirus pandemic ...
Partner-Delivered HIV Self-Testing Can Up Linkage to Care drugs
January 03, 2019
Partner-delivered HIV self-testing (HIVST) with financial incentives or reminders can increase the odds of male partners being linked to care or prevention, according to a study published online Jan. 2 in PLOS Medicine....